530233 Stock Overview Manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Auro Laboratories Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Auro Laboratories Historical stock prices Current Share Price ₹281.95 52 Week High ₹307.20 52 Week Low ₹118.10 Beta 0.62 1 Month Change 44.26% 3 Month Change 46.81% 1 Year Change 150.62% 3 Year Change 172.81% 5 Year Change 492.95% Change since IPO 13,586.89%
Recent News & Updates
Investor sentiment improves as stock rises 19% Dec 19
Auro Laboratories Limited Announces Resignation of Shaan Jain as Chief Financial Officer Dec 19
Investor sentiment improves as stock rises 16% Dec 05
Investor sentiment deteriorates as stock falls 22% Nov 18
Now 25% undervalued Nov 13
Second quarter 2025 earnings released: EPS: ₹0.57 (vs ₹3.16 in 2Q 2024) Nov 13 See more updates
Investor sentiment improves as stock rises 19% Dec 19
Auro Laboratories Limited Announces Resignation of Shaan Jain as Chief Financial Officer Dec 19
Investor sentiment improves as stock rises 16% Dec 05
Investor sentiment deteriorates as stock falls 22% Nov 18
Now 25% undervalued Nov 13
Second quarter 2025 earnings released: EPS: ₹0.57 (vs ₹3.16 in 2Q 2024) Nov 13
Auro Laboratories Limited to Report Q2, 2025 Results on Nov 11, 2024 Nov 06
Investor sentiment improves as stock rises 19% Oct 17
First quarter 2025 earnings released: EPS: ₹1.21 (vs ₹1.14 in 1Q 2024) Aug 10
Auro Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024 Jul 31
Auro Laboratories Limited Announces Resignation of Sweta Agarwal as Company Secretary and Compliance Officer, Effective July 30, 2024 Jul 23
Investor sentiment deteriorates as stock falls 17% Jun 01
Full year 2024 earnings released: EPS: ₹12.50 (vs ₹3.92 in FY 2023) May 27
Auro Laboratories Limited to Report Q4, 2024 Results on May 25, 2024 May 19
Investor sentiment improves as stock rises 26% May 02
Less than half of directors are independent Apr 08
Investor sentiment improves as stock rises 15% Apr 02
Third quarter 2024 earnings released: EPS: ₹4.39 (vs ₹0.59 in 3Q 2023) Feb 07
Auro Laboratories Limited to Report Q3, 2024 Results on Feb 06, 2024 Feb 01
Investor sentiment improves as stock rises 21% Jan 01
Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer Dec 22
Investor sentiment improves as stock rises 23% Nov 16
Second quarter 2024 earnings released: EPS: ₹3.16 (vs ₹0.34 in 2Q 2023) Nov 11
Auro Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023 Nov 04 Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023 Sep 26
Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director Sep 24
Less than half of directors are independent Aug 30
Auro Laboratories Limited, Annual General Meeting, Sep 23, 2023 Aug 30
Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director Aug 24
First quarter 2024 earnings released: EPS: ₹1.14 (vs ₹0.13 in 1Q 2023) Aug 01
Auro Laboratories Limited to Report Q1, 2024 Results on Jul 31, 2023 Jul 24
Full year 2023 earnings released: EPS: ₹3.92 (vs ₹4.56 in FY 2022) May 18
Investor sentiment improves as stock rises 23% May 17
Investor sentiment improves as stock rises 16% Apr 05
Third quarter 2023 earnings released: EPS: ₹0.59 (vs ₹0.98 in 3Q 2022) Feb 15
Auro Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023 Feb 01
Second quarter 2023 earnings released: EPS: ₹0.34 (vs ₹1.14 in 2Q 2022) Nov 20
Auro Laboratories Limited to Report Q2, 2023 Results on Nov 14, 2022 Nov 05
First quarter 2023 earnings released: EPS: ₹0.13 (vs ₹1.71 in 1Q 2022) Aug 03
Auro Laboratories Limited to Report Q1, 2023 Results on Aug 02, 2022 Jul 20
Investor sentiment improved over the past week Jul 12
Full year 2022 earnings released: EPS: ₹4.56 (vs ₹11.52 in FY 2021) Jun 04 Auro Laboratories Limited Announces Management Changes
Auro Laboratories Limited to Report Q4, 2022 Results on May 30, 2022 May 21
Investor sentiment improved over the past week Jan 04
Investor sentiment improved over the past week Oct 08
Whole Time Director recently bought ₹86k worth of stock Sep 22
Investor sentiment deteriorated over the past week Aug 12
First quarter 2022 earnings released: EPS ₹1.71 (vs ₹2.22 in 1Q 2021) Aug 09
Investor sentiment improved over the past week Jun 29
Full year 2021 earnings released: EPS ₹11.52 (vs ₹6.51 in FY 2020) Jun 23
Investor sentiment improved over the past week Apr 24
Auro Laboratories Limited Appoints Mrs. Kavita Sharma as Independent Director Feb 13
Auro Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021 Feb 04
Investor sentiment improved over the past week Jan 11
New 90-day high: ₹98.80 Jan 11
Second quarter 2021 earnings released: EPS ₹3.62 Nov 07
Market bids up stock over the past week Nov 06
Auro Laboratories Limited to Report Q2, 2020 Results on Nov 05, 2020 Oct 28
New 90-day high: ₹67.65 Oct 07
New 90-day high - ₹58.10 Sep 15
First quarter earnings released Sep 02
Auro Laboratories Limited to Report Q1, 2021 Results on Aug 31, 2020 Aug 22
New 90-day high - ₹52.25 Aug 03 Shareholder Returns 530233 IN Pharmaceuticals IN Market 7D 22.5% 0.8% -4.2% 1Y 150.6% 39.7% 19.1%
See full shareholder returns
Return vs Market: 530233 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility Is 530233's price volatile compared to industry and market? 530233 volatility 530233 Average Weekly Movement 8.6% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 530233's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 530233's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, that includes potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid.
Show more Auro Laboratories Limited Fundamentals Summary How do Auro Laboratories's earnings and revenue compare to its market cap? 530233 fundamental statistics Market cap ₹1.76b Earnings (TTM ) ₹62.27m Revenue (TTM ) ₹388.63m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 530233 income statement (TTM ) Revenue ₹388.63m Cost of Revenue ₹162.51m Gross Profit ₹226.12m Other Expenses ₹163.85m Earnings ₹62.27m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 9.99 Gross Margin 58.19% Net Profit Margin 16.02% Debt/Equity Ratio 78.9%
How did 530233 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 01:16 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Auro Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
